Affimed Announces Presentation of Preclinical Data on AFM13-targeted NK cells at the 35th Annual Meeting of the Society for I...
October 14 2020 - 5:15PM
Heidelberg, Germany, October 14, 2020 –
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer, today announced that preclinical data from its
collaboration with The University of Texas MD Anderson Cancer
Center and Washington University School of Medicine will be
presented in an oral presentation at the 35th Annual Meeting of the
Society for Immunotherapy of Cancer (SITC), which will be held
virtually on November 9-14, 2020.
Details of the oral presentation:
Title: AFM13-targeted blood and
cord-blood-derived memory-like NK cells as therapy for CD30+
malignancies
Abstract ID: 349
Authors: Lucila Kerbauy, Nancy D. Marin, Mecit
Kaplan, Pinaki Banerjee, Melissa Berrien-Elliott, Michelle
Becker-Hapak, Rafet Basar, Mark Foster, Luciana Garcia Melo, Carly
Neal, Ethan McClain, May Daher, Ana Karen Nunez Cortes, Francesca
Wei Inng Lim, Mayela Carolina Mendt, Timothy Schappe, Li Li, Hila
Shaim, Mayra Hernandez Sanabria, Pamela Wong, Enli Liu, Sonny Ang,
Rong Cai, Vandana Nandivada, Vakul Mohanty, Yifei Shen, Natalia
Baran, Natalie Fowlkes, Ken Chen, Luis Muniz-Feliciano, Joachim
Koch, Martin Treder, Wolfgang Fischer, Oswaldo Keith Okamoto, Yago
Nieto, Richard E. Champlin, Elizabeth J. Shpall, Todd A. Fehniger,
Katayoun Rezvani
Date: November 11, 2020 during the concurrent
session Innate Immunity: The Next Generation of Targets for
Anti-Cancer Immunotherapy (3:45 – 5:15 pm EST).
Abstract Release: All abstracts will be
available on November 09, 2020 at 8:00 am EST.
For more details about the SITC Virtual Annual Meeting please
visit: www.sitcancer.org/2020/home.
About AFM13
AFM13 is a first-in-class CD30/CD16A ROCK®-derived bispecific
innate cell engager (ICE®) that induces specific and selective
killing of CD30-positive tumor cells by engaging and activating
natural killer (NK) cells and macrophages, thereby leveraging the
power of the innate immune system. AFM13 is Affimed’s most advanced
ICE® clinical program, and it is currently being evaluated as a
monotherapy in a registration-directed trial in patients with
relapsed/refractory peripheral T-cell lymphoma (REDIRECT). The
study is actively recruiting and can be found at
www.clinicaltrials.gov using the identifier NCT04101331.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer. Affimed’s fit-for-purpose ROCK® platform allows
innate cell engagers to be designed for specific patient
populations. The company is developing single and combination
therapies to treat hematologic and solid tumors. The company is
currently enrolling patients into a registration-directed study of
AFM13 for CD30-positive relapsed/refractory peripheral T cell
lymphoma and into a Phase 1/2a dose escalation/expansion study of
AFM24 for the treatment of advanced EGFR-expressing solid tumors.
For more information, please visit www.affimed.com.
Affimed Investor Contact
Alex Fudukidis Head of Investor Relations E-Mail:
a.fudukidis@affimed.com Tel.: (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024